Home / Publication / Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-concept, Randomised, Placebo-controlled Trial

刊物

Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-concept, Randomised, Placebo-controlled Trial

Author(s): Faustino Torrico, Joaquim Gascon, Lourdes Ortiz, Cristina Alonso-Vega, María-Jesús Pinazo, Alejandro Schijman, Igor Almeida, Fabiana Alves, Nathalie Strub-Wourgaft, Isabela Ribeiro, E1224 Study Group

Year: 2018 年 1 月 15 日

ADC Dose Optimization: Applying Model-Informed Strategies in Development

博客

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

博客

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

网络研讨会

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

博客

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-concept, Randomised, Placebo-controlled Trial

Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-concept, Randomised, Placebo-controlled Trial

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

订阅时事通讯

快捷链接

解决方案

联系我们